BC Platforms AG, a world leader in genomic data management and analytics, today announces that it has partnered with Medaffcon Oy, a company specialized in generating Real World Evidence for health-related decision-making. Medaffcon provides medical, scientific and market access services to international pharmaceutical and biotechnology industries as well as health care operators. The partnership focuses on harmonizing complex genomic and clinical data from multiple sources applying joint specialist knowledge and technological capabilities.
With over 20 years’ experience in working with genomics and information technology, BC platforms has built a global network of biobanks providing a safe and secure environment for biobanks and researchers to determine data availability and advance research.
Since its establishment in 2009, Medaffcon has been working as an expert organization with a core competence in scientific and health economic expertise. Medaffcon has also been pioneering industry-driven biobank research efforts, since the establishment of the first biobanks in Finland. Medaffcon is owned by the PHOENIX group, a large integrated European Healthcare provider ensuring that patients and the public have access to high-quality healthcare across the Europe.
Jaana Ahlamaa, Medical and Market Access Director at Medaffcon, commented on the partnership, “We are very excited to be partnering with BC Platforms and their world leading network of biobanks through their BCRQUEST service. The collaboration will expand our capabilities of accessing and combining different Finnish and international data sources to advance research.”
Tero Silvola, CEO of BC Platforms, said “We are delighted to partner with Medaffcon, part of the PHOENIX group. Our goal is to combine our global platform to leverage Medaffcon´s extensive expertise in key markets in order to utilize Real World Evidence faster and more effectively.”
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier EMA CHMP acknowledges that n
LubioScience GmbH, Switzerland’s leading Life Sciences platform, expands its product portfolio with the addition of fresh human blood products and biospecimens provided by Research Donors from the UK.
Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024 Topline results from the completed Phase I/II will be reported in the first half of 2024
InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces that the company's most advanced artificial intelligence platform has uncovered novel cellular signaling modes of action which enable InterAx to design efficacious orally available drugs for diabetes, obesity, and immuno oncology. Particularly promising results are coming from the
Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements The company is looking to expand development and commercial collaborations with industry leaders
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1